Variability in blood-based amyloid-beta assays: the need for consensus on pre-analytical processing.
Andrew D Watt1, Keyla A Perez, Alan R Rembach
1Department of Pathology, The University of Melbourne, Parkville, Melbourne, VIC, Australia.
Journal of Alzheimer'S Disease : JAD
|March 20, 2012
Summary
Standardizing blood sample collection is crucial for reliable Alzheimer's disease (AD) diagnostics. Inconsistent preanalytical methods hinder the development of blood-based biomarkers for early AD detection.
Area of Science:
- Neuroscience
- Biochemistry
- Medical Diagnostics
Background:
- Effective Alzheimer's disease (AD) therapeutics require early intervention during the presymptomatic stage.
- Identifying individuals at risk for AD progression necessitates reliable biomarkers.
- Current neuroimaging and cerebrospinal fluid biomarkers face challenges for general population screening.
Purpose of the Study:
- To review and compare preanalytical processing techniques for blood-based amyloid-beta (Aβ) measurement.
- To investigate the impact of preanalytical variability on diagnostic marker results.
- To identify shortcomings in methodological reporting and propose standardization.
Main Methods:
- Systematic review of 87 recent articles on Aβ measurement in blood.
- Comparative analysis of reported preanalytical sample-handling techniques.
- Assessment of methodological reporting consistency.
Main Results:
- Significant variability exists in preanalytical processing methods across studies.
- Discrepancies in sample handling likely contribute to inconsistent blood-based biomarker results.
- Inadequate reporting of preanalytical techniques is prevalent in the field.
Conclusions:
- Standardization of blood collection and processing is essential for reliable blood-based AD biomarkers.
- Addressing preanalytical variability is critical to advance early AD detection.
- A consensus-based standardized methodology is recommended for future research.
